Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.82 |
| ▸ | PDE4A | P27815 | 10/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516503 | 0.91 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11073850 | 0.80 | ADORA2B (0.78) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9429985 | 0.80 | PDE4A (0.85) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL4623640 | 0.79 | ADORA2A (0.76) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11455885 | 0.77 | ADORA2B (0.69) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11665017 | 0.77 | ADORA2B (0.72) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7597424 | 0.76 | ADORA2A (0.67) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL10647729 | 0.73 | ADORA2B (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL941660 | 0.70 | ADORA2B (0.70) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5134359 | 0.70 | ADORA2A (0.66) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | HOECHST AKTIENGESELLSCHAFT | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | EPX, XDH, MPO | ADORA2B 163/4885ADORA2A 112/4885PDE4A 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.